OTC · Drug Manufacturers - Specialty & Generic

ARYx Therapeutics, Inc. (ARYX) Stock

$0.00 OTC: ARYX Healthcare

Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications.

Valuation

MetricValue
Price$0.00
Market Cap$16731
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-0.05
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1100.00%
ROA-74.86%
ROCE-838.60%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-4.00
Current Ratio0.47

Annual Financials (USD)

Metric20052006200720082009
Revenue$0$5.0M$4.0M$20.0M$0
Operating Profit$-28.0M$-28.0M$-29.0M$-30.0M$-31.0M
Net Profit$-28.0M$-27.0M$-28.0M$-31.0M$-33.0M
EPS$-30.73$-26.84$-2.93$-1.65$-1.21
Op Margin—-596.9%-692.6%-154.2%—

Balance Sheet (USD)

Metric20052006200720082009
Total Assets$33.0M$57.0M$70.0M$51.0M$12.0M
Total Liabilities$100.0M$150.0M$34.0M$24.0M$15.0M
Cash$12.0M$19.0M$55.0M$36.0M$7.0M
Borrowings$11.0M$10.0M$7.0M$15.0M$12.0M

Cash Flow (USD)

Metric20052006200720082009
Operating Cash Flow$-22.0M$-4.0M$-28.0M$-45.0M$-35.0M
Investing Cash Flow$6.0M$-19.0M$23.0M$-3.0M$8.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-2.0M$6.0M$37.0M$-19.0M$-29.0M
Free Cash Flow$-26.0M$-5.0M$-28.0M$-46.0M$-35.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.15
FCF Yield-209838.03%
Quick Ratio1.01
Interest Coverage-15.56
Return 1Y0.00%
Return 3Y0.00%
Return 5Y—

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATTBFAbattis Bioceuticals Corp. $0.00 — -0.01 $14334 0.00%
NNRXNutranomics, Inc. $0.00 — -0.07 $816232 0.00%
NSPDFNaturally Splendid Enterprises Ltd. $0.04 +0.00% -0.25 $881665 0.00%
NUNZNunzia Pharmaceutical Company $0.00 — 0.00 $43451 0.00%
ONSSOnassis Holdings Corp. $0.00 — -0.18 $3926 0.00%

About ARYx Therapeutics, Inc.

Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.

ARYx Therapeutics, Inc. (ARYX) stock trades at $0.00 with a market capitalization of $16731. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, ARYx Therapeutics, Inc. generates a return on equity (ROE) of 1100.00% — well above the market average, a sign of a high-quality business, return on capital employed of -838.60%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.aryx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides